No psychedelic biotech M&A or licensing deal >$50M is announced within 60 days; CMPS continues underperforming MMED absent a Phase 3 readout catalyst.

In the business world, a merger or licensing deal worth more than $50 million is a sign that big money is taking a sector seriously. This prediction says no such deal will happen in psychedelic biotech before mid-October 2026. It also says that a company called MMED (Mind Medicine) is outperforming a competitor called CMPS (Compass Pathways) in stock performance, and that gap will likely continue without a major scientific milestone from Compass.

Institutional capital waits on de-risked assets. Ibogaine political noise doesn't move deal committees. MMED's relative strength signals where smart money positions.